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CHARACTERIZATION OF PULMONARY INFECTIONS 
IN THE LATE POSTOPERATIVE PERIOD OF KIDNEY 
TRANSPLANTATION: AN INTEGRATIVE REVIEW
Caracterização de infecções pulmonares no pós-operatório 
tardio de transplante renal: uma revisão integrativa
Caracterización de infecciones pulmonares en el postoperatorio 
tardío de trasplante renal: una revisión integrativa
ABSTRACT
Objective: The aim of this study was to characterize the nature and frequency of pulmonary 
infections in late post-kidney transplant adult recipients. Methods: A bibliographic review 
was conducted in the following electronic databases: PubMed, SciELO and Web of Science. 
The study eligibility criteria were articles published between the years 2010 and 2015, in 
English, Portuguese or Spanish, comprising clinical trials, randomized or not, case-control 
studies, cohort studies, and longitudinal studies in humans. Articles whose research subjects 
were aged under 18 years were excluded, as well as repeated articles, which appeared in 
more than one of the databases. The keywords used and combined in the research were: 
pneumonia, lung infection, infection, kidney transplantation, hospitalization. Results: The 
most common etiologic agents are Pneumocystis jirovecii, Mycobacterium tuberculosis 
and Aspergillus fumigatus. Pulmonary infections are, in a large number, due to the 
immunosuppressive regimen, extensive length of time on hemodialysis, graft dysfunction 
and interhuman transmission. Often, such infections evolve with progressive dyspnea and 
acute respiratory failure, thus requiring invasive or non-invasive mechanical ventilation. 
Conclusion: The evidences point out a high prevalence of pulmonary infections in kidney 
transplant recipients. 
Descriptors: Hospitalization; Kidney Transplantation; Respiratory Tract Infections.
RESUMO
Objetivo: Caracterizar a natureza e frequência das infecções pulmonares em pacientes 
adultos pós-transplantados renais tardios. Métodos: Foi realizado um estudo de revisão 
bibliográfica nas seguintes bases de dados eletrônicas: PubMed, Scielo e Web of Science. 
Os critérios de elegibilidade do estudo foram: artigos publicados entre os anos de 2010 e 
2015, nos idiomas inglês, português ou espanhol, do tipo: ensaios clínicos, randomizados ou 
não, estudos de caso-controle, estudos de coorte e estudos longitudinais em humanos. Foram 
excluídos os artigos cujos participantes da pesquisa fossem menores de 18 anos de idade, 
além dos artigos duplicados em mais de uma das bases de dados. As palavras-chave utilizadas 
e combinadas na pesquisa foram: pneumonia, infecção pulmonar, infecção, transplante 
renal, hospitalização. Resultados: Os agentes etiológicos mais incidentes são Pneumocystis 
jirovecii, Mycobacterium tuberculosis e Aspergillus fumigatus. As infecções pulmonares são 
devidas, em grande número, ao regime imunossupressor, tempo prolongado de hemodiálise, 
disfunção de enxerto e transmissão inter humana. Frequentemente, essas infecções evoluem 
com dispneia progressiva e insuficiência respiratória aguda, sendo necessária ventilação 
mecânica invasiva ou não invasiva. Conclusão: As evidências científicas apontam uma alta 
prevalência de infecções pulmonares nos pacientes transplantados renais.
Descritores: Hospitalização; Transplante de Rim; Infecções Respiratórias.
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RESUMEN
Objetivo: El objetivo del estudio fue caracterizar la naturaleza 
y la frecuencia de las infecciones pulmonares de pacientes 
adultos pos trasplante renal tardío. Métodos: Se realizó un 
estudio de revisión bibliográfica en las siguientes bases de datos 
electrónicas: PubMed, Scielo y Web of Science. Los criterios de 
elegibilidad del estudio fueron: artículos publicados entre los 
años de 2010 y 2015 en los idiomas inglés, portugués o español, 
del tipo ensayos clínicos randomizados o no, estudios de caso-
control, estudios de cohorte y estudios longitudinales en humanos. 
Fueron excluidos los artículos cuyos los participantes de la 
investigación tenían menos de 18 años de edad, además de los 
artículos repetidos en más de una base de datos. Las palabras-
clave utilizadas y asociadas en la investigación fueron: neumonía, 
infección pulmonar, infección, trasplante renal, hospitalización. 
Resultados: Los agentes etiológicos más incidentes son la 
Pneumocystis jirovecii, el Mycobacterium tuberculosis y el 
Aspergillus fumigatus. Las infecciones pulmonares son causadas, 
en su mayoría, por el régimen inmunosupresor, el largo tiempo 
de hemodiálisis, la disfunción del injerto y la trasmisión inter 
humanos. Esas infecciones evolucionan, con frecuencia, con 
disnea progresiva e insuficiencia respiratoria aguda y la necesidad 
de ventilación mecánica invasiva o no invasiva. Conclusión: Las 
evidencias científicas apuntan elevada prevalencia de infecciones 
pulmonares en los pacientes trasplantados renales.
Descriptores: Hospitalización; Trasplante de Riñon; Infecciones 
del Sistema Respiratorio.
INTRODUCTION
The most common solid organ transplantation in the 
world is kidney transplantation, which is the treatment of 
choice for end-stage renal disease (ESRD). In Brazil, it is 
the most frequently performed type of transplant surgery 
- between January and June 2015, 2664 renal transplants 
were performed(1). Compared to chronic dialysis, kidney 
transplantation is cost-effective, provides improved 
quality of life and a progressive benefit to the patient’s 
life expectancy. The graft survival rate has consistently 
increased over the past decades(2).
The use of immunosuppression in patients after kidney 
transplantation can predispose to opportunistic infections 
such as the ones affecting the respiratory system(3). Due to 
immunosuppression, patients with functioning grafts are 
exposed to different pathogens, which impact on morbidity 
and mortality, thus explaining why infection is the second 
cause of death in renal transplant patients(1). Lung infections 
such as pneumonia and lower respiratory tract infections 
are among the postoperative complications, as well as 
non-infectious complications, such as atelectasis, pleural 
effusion and diaphragmatic dysfunction.
During the period of maximum immunosuppression 
(within six months after transplantation), the risk of viruses 
or opportunistic agents is high. Lung infections represent 
20% of all infections. Immunosuppressive drugs can induce 
a negative effect on the lungs, such as toxicity, particularly in 
renal transplant patients, leading to interstitial pneumonitis, 
obliterative bronchiolitis and pneumonia(4).
This study aimed to characterize the frequency 
and nature of lung infections in adult patients in the late 
postoperative period of kidney transplantation. 
METHODS
This is a literature review, consisting of a search 
conducted in the following electronic databases: PubMed, 
SciELO and Web of Science.
The study eligibility criteria were: articles published 
between the years 2010 and 2015, in English, Portuguese, 
or Spanish, reporting clinical trials, whether randomized or 
not, case-control studies, cohort studies, and longitudinal 
studies conducted in humans. Articles whose research 
subjects were under 18 years of age were excluded, in 
addition to those duplicated, found in more than one 
database.
The research used and combined the following 
keywords: pneumonia, lung infection, infection, kidney 
transplantation, hospitalization, and their correspondents 
in Portuguese and Spanish. The selected articles were then 
analyzed by two researchers through the reading of the title, 
abstract and full text, respectively.
The outcomes analyzed were: type of study, year of 
publication, number of patients, study site, data collection 
instrument, elapsed time after transplantation, infection 
etiologic agent, length of hospital stay, period and/or need 
for mechanical ventilation, death rate, details on the clinical 
status evolution, and whether there was the progress to Acute 
Respiratory Distress Syndrome (ARDS) and performance 
of alveolar recruitment maneuver.
RESULTS AND DISCUSSION
After the researchers have jointly analyzed and 
identifyied the inclusion and exclusion criteria, 77 articles 
were selected. Of these, 22 articles were excluded (3 were 
non-scientific articles and 19 lacked relationship to the 
topic being discussed), and a total of 55 items remained for 
reading and analysis, as shown in the following flowchart 
(Figure 1). The demographic characteristics of patients in 
their study are listed in Table I, in which only three selected 
articles, classified as literature review, were not included. 
The remaining results will be presented in topics, for better 
understanding by the reader.
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Figure 1 - Flowchart of scientific articles selection.
The types of studies found were case 
reports(9,12,17,22,25,30,37,41,42,44,47,50,51,57,58), retrospective studies (5,7,8,1
0,11,21,24,28,29,31,32,35,39,43,45,56), cohort(13,14,18,19,23,27,33,34,36,38,40,46,48,49,55), 
case-control(6,15,20,26,59) and literature review(16,33,52). The 
selected articles had their researches held in China(9,11,45,46,50), 
Spain(12,14,38,39,58), Tunisia(33), Belgium(57), Denmark 
(15,19), Malaysia(17), Germany(7,18,23,28), Turkey(21,25,32,34,36), 
Brazil(22), Slovenia(24), Netherlands(26,27,55), Taiwan(8,31,49,56), 
France(5,6,29,43), Colombia(35,41), India(44), United States(10,51,52,59), 
Portugal(30), Italy(42), Australia(47), Mexico(48) and Greece(40). 
It stands out that, according to the established inclusion 
criteria, only one study carried out by Brazilian researchers 
was found, which emphasizes the need for national scientific 
progress regarding this issue.
Etiologic agents
The most commonly found etiologic agents in 
the selected articles were Pneumocystis jirovecii(5-30), 
Mycobacterium tuberculosis(29,31-36) and Aspergillus 
fumigatus(10,14,21,32,37-41). The results on these three main 
etiologic agents will be following displayed in separately.
The reported techniques for the diagnosis of the 
etiologic agents were: bronchoscopy with bronchoalveolar 
lavage(5,6,9,10,12-14,17,19-22,25,26,29,30,32,36,38,39,41-54), polymerase 
chain reaction(6-8,14,15,17-20,22,23,25,27-29,43-45,49,52),histopatholo
gy(28,35,37,55), lung biopsy(10,33,36,42,45,51,53,56), radiography and 
computed tomography(7,9-12,21,22,29,34,41-43,45,47,49,51,54-58), Ziehl-
Neelsen staining(21,25,33,41,53,57), Gram technique(41) and 
immunofluorescence microscopy(15,17,27).
Articles selected in the 
databases n=77
Articles excluded for being 
non-scientific n=3
Articles excluded for being 
non-related to the subject 
matter n=19
Total of articles included 
in the study n=55
TABLE I - General characteristics of 52 of the 55 selected studies. Campinas, SP, 2010-2015.
Author/year n Age in years(mean ± SD)
Length of 
ICU stay      
in days
Need for IMV 
(quantitative) Deaths (%)
Brunot V. et al., 2012(5) 9 NI 8 to 15 3 NI
Le Gal S. et al., 2012(6) 18 62 NI NI NI
Pliquett RU. et al., 2012(7) 29 54.9 ± 14.9 NI NI 34
Yang CY. et al., 2012(8) 20 54.5 ± 13.0 NI 14 (ARF) 50 (ARI)
Tu GW. et al., 2013(9) 3 46.3 35 NI 33 (SEPSE)
Chen G. et al., 2010(10) 53 cases and 2520 controls
47.3 ± 13.1 years - cases
42.6 ± 12.5 years - 
controls
NI NI 45 (PNM)
Song T. et al., 2010(11) 13 37 NI NI NI
Perez-Ordoño L. et al., 2014(12) 4 50.5 21 4 NI
Phipps LM. et al., 2011(13) 14 46.6 ± 13.2 NI 10 (ARF) 14 (PNM)
Hoyo I. et al., 2012(14) 1656 51 NI NI 1.5 (PNM)
Rostved AA. et al., 2013(15) 16 cases and 32 controls
46 years - cases
46 years - controls 25 NI NI
Boer MGJ. et al., 2011(16) 50 cases and 99 controls
57.4 years - cases
52.1 controls NI 4 6 (PNM)
Iqbal MAH. et al., 2012(17) 1 38 NI NI NI
Fritzsche C. et al., 2013(18) 70 55.0 ± 12 NI NI NI
Leth S. et al., 2014(19) 46 59.2 NI NI NI
De Castro N. et al., 2010(20) 11 53 NI NI 0,9 (PNM)
Dizdar OS. et al., 2014(21) 82 38 ± 12 NI NI 34 (PNM)
Ramalho J. et al., 2014(22) 1 54 NI NI NI
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Pneumocystis jirovecii
Pneumonia caused by the fungus Pneumocystis jirovecii 
(PJ) is recognized as an important cause of morbidity and 
mortality among patients taking immunosuppressants after 
solid organ transplantation. Kidney recipients are patients 
at high risk of infection in the transplantation postoperative 
period, especially in the first two years, with a mortality rate 
that amounts to over 50%(16,18,22-24,28).
Maruschke M. et al., 2014(23) 7 64.3 ± 13.9 NI NI 42 (PNM)
Borstnar S. et al., 2013(24) 13 49 ± 4 NI NI 23 (PNM)
Metan G. et al., 2011(25) 1 40 25 NI  NI
Struijk GH. et al., 2011(26) 9 56 NI NI NI
Eitner F. et al., 2011(28) 60 cases and 60 controls
53.9 ± 13.9 - cases
51.7 ± 13.5 - controls
NI 23 26 (PNM)
Bige N. et al., 2014(29) 83 55.6 19 32 37 (PNM)
Bento C. et al., 2014(30) 1 51 22 NI NI
Chen CH. et al., 2014(31) 153 46.6 ± 12.7 NI NI NI
Eyüboğlu FÖ. et al., 2013(32) 90 42.3 ± 12.3 19 27 (PNM) 62 (PNM)
Boubaker K. et al., 2013(33) 16 32.2 ± 12.7 NI NI 6.2 (TB)/6.2 (SEPSIS)
Kupeli E. et al., 2011(34) 136 36.3 ± 12.2 NI NI NI
Higuita LMS. et al., 2014(35) 12 52.5 14 to 72 NI 16 (TB)
Ersan S. et al., 2011(36) 9 46.7 ± 11.7 NI NI 11 (TB)
Nasim A. et al., 2011(37) 1 35 NI NI NI
Hoyo I. et al., 2010(38) 610 52.3 NI 15 1,4 (PNM)
Hoyo I. et al., 2014(39) 9 58.9  NI  NI NI
Moloudi E. et al., 2012(40) 27 42.7 ± 12.3  19  27 (PNM) 62 (PNM)
Encarnación AA. et al., 2012(41) 1 41  20  NI  100 (PNM)
Rizza V. et al., 2011(42) 1 32  10  NI NI
Canet E. et al., 2011(43) 200 56  10  NI NI
Kute VB. et al., 2013(44) 1 46  NI  NI  NI
Jiang T. et al., 2012(45) 89 43.7 NI  NI  NI
Tu G. et al., 2015(46) 60 53.5  20  21 (ARF)  13 (ARI)
Jabbar Z. et al., 2013(47) 1 70  NI  NI  NI
Valdez-Ortiz R. et al., 2011(48) 350 37.96 ± 11.4  NI  NI  3.7 (PNM)
Shih CJ. et al., 2014(49) 33 56.9 ± 11.4  12 33 (PNM) 45 (PNM)
He Q. et al., 2011(50) 2 48  NI NI NI
Cunha BA. et al., 2012(51) 1 77 37 NI 100 (PNM)
Gainer SM. et al., 2012(52) 18 46 18  4 (ARF) 16 (OF)
Baas MC. et al., 2014(55) 13 50  NI  NI NI
Ou SM. et al., 2012(56) 109 47.6 ± 11.2 NI  NI 22 (PNM)
Ho TA. et al., 2010(57) 1 54 14  NI NI
Fraile P. et al., 2013(58) 1 27 NI  NI  NI
Simkins J. et al., 2014(59) 13 cases and 39 controls
53 ± 18 cases and 55 ± 
16 controls NI NI 46 (PNM)
SD: Standard Deviation; OF:Organ Failure; ARF: Acute Respiratory Failure; n: Number of patients; PNM: Pneumonia; TB: Tuberculosis; 
ICU: Intensive Care Unit; IMV: Invasive Mechanical Ventilation; NI: not informed in the article.
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The causes of PJ pneumonia outbreaks and their specific 
risk factors are not yet clearly defined. There are suppositions 
that closer contact and inter-human transmission, 
reactivation of latent infection, environmental exposure 
and more sensitive analysis contribute to the PJ increased 
incidence(13,16,24). Other studies suggest the transmission 
via airborne droplets, low CD4 T-cell count, and the graft 
rejection as causes of PJ infection(5,6,19,20). The reduced 
immunity resulting from the immunosuppressive treatment 
and cytomegalovirus infections has also influenced on the 
higher number of pneumocystis pneumonia cases in renal 
transplant patients(5,6,19,20). Other factors for the development 
of PJ pneumonia include impaired renal functioniong and 
episodes of graft rejection(8,28).
The most evident radiographic and tomographic 
findings after the diagnosis of PJ pneumonia were 
diffuse bilateral infiltrates, ground-glass pattern and/or 
consolidation throughout the entire lung(11,17,26). The most 
frequently reported clinical status comprises progressive 
dyspnea, hypoxemia, fever, non-productive cough, and 
acute respiratory failure (ARF), with frequent need for 
endotracheal intubation(12,20,25,26). The most common 
causes of ARF in kidney transplant patients are bacterial 
pneumonia, cardiogenic pulmonary edema and acute 
respiratory distress syndrome (ARDS). Such respiratory 
impairment is associated with increased mortality and graft 
loss, and prophylaxis is essential(43).
Mycobacterium tuberculosis
Mycobacterium tuberculosis (MT) pulmonary 
tuberculosis is an important cause of mortality in 
endemic countries, and its incidence is 20 to 70 times 
higher in renal transplant patients, mainly because of 
their immunosuppressed state(33,35,53,60). Donor-derived 
tuberculosis has already been reported in kidney, liver and 
lung transplants. The bacteria can also be acquired after the 
transplant surgery, with higher infection rate in developing 
countries(53).
Similarly, the extrapulmonary or disseminated 
tuberculosis has a higher occurrence in the transplant 
recipient population compared with the general population. 
Its symptoms and clinical manifestations are often non-
specific, rendering it difficult to reach an early diagnosis(36,61). 
Risk factors include direct contact with carriers of the 
bacteria, AB blood group, hepatitis C, graft dysfunction, 
serum creatinine, use of immunosuppressants, prolonged 
pre-transplant hemodialysis time, diabetes mellitus, chronic 
obstructive pulmonary disease (COPD), autoimmune 
diseases and cirrhosis of the liver(33,56).
The clinical status is commonly characterized by fever, 
weight loss, pleuritic syndrome and pulmonary infection 
resistant to antibiotic therapy. Chest radiographs show 
miliary pattern, pleural effusion, cavitations, pulmonary 
nodules, consolidations, air bronchograms and pulmonary 
infiltrates(33,35,36,53). The diagnosis of tuberculosis is, in 
fact, late and often requires invasive procedures such as 
bronchoscopy with bronchoalveolar lavage, or biopsy of the 
lung tissue or tissue involved(53).
Aspergillus fumigatus
Aspergillosis is one of the most important opportunistic 
fungal infections in solid organ transplant recipients, with 
high mortality rate. The majority of cases occur within 90 days 
post-transplantation(14). The incidence of fungal infections 
such as aspergillosis varies between 1 and 14%, with an 
incidence of 74% in the first year after renal transplantation. 
The fungus Aspergillus fumigatus causes four known 
syndromes: bronchopulmonary allergic aspergillosis, 
aspergilloma, chronic necrotizing aspergillosis and invasive 
pulmonary aspergillosis. Pulmonary aspergillosis may 
progress to an invasive disease with mortality rate close 
to 63%. The main risk factors for aspergillosis are graft 
dysfunction, immunosuppressive regimen, and renal failure 
and requiring hemodialysis(37,41).
The clinical status shows productive cough, hemoptysis, 
chest pain, dyspnea and fever. The clinical findings 
range from the colonization of a previous lung cavity to 
parenchymal and vascular invasion. Radiologically, there 
is involvement of the upper lobes, cavitation, pleural 
thickening, peribronchial consolidation, ground-glass 
opacification areas, and centrilobular nodules(37,39).
Other etiologic agents 
Other less frequently cited etiologic agents, with no 
description of risk factors related to their onset, incidence 
of percentage, clinical or radiological findings, are: 
Pseudomonas aeruginosa(21,29,32,38,43,46,49), Staphylococcus 
aureus(32,43,45,46,48,49), Klebsiella pneumoniae(32,46,49,59), 
Acinetobacter baumannii(34,49), Candida albicans(32,45,48), 
Cytomegalovirus(7,29,40,45), Herpes simplex(42,43,51), 
Adenoviruses(14), Burkholderia pseudomallei(47), Escherichia 
coli(32,43,46,48), H1N1(52,58), Haemophilus influenzae(21), 
Legionella pneumophila(38), Lophomonas blattarum(50), 
M. catharralis(32), Mycobacterium avium(57), Nocardia 
spp(14), Stenotrophomonas maltophilia(21,32), Streptococcus 
hemolyticus(46), Streptococcus pneumoniae(32,34,38,43), 
Enterococcus(48), Mycobacterium intracellulare(57) 
and Varicella zoster(14). A case-cohort study evaluated 
the incidence and risk factors for everolimus-induced 
pneumonitis in post-renal transplant patients(55). Two articles 
have brought the incidence of bronchiolitis obliterans 
organizing pneumonia in association with infectious 
pulmonary conditions44,51).
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Acute Respiratory Distress Syndrome 
ARDS is a condition characterized by an inflammatory 
process which results in increased alveolar-capillary 
permeability, with a consequent interstitial and alveolar 
edema. Its main signs are severe hypoxemia, low lung 
compliance, and bilateral infiltrates on chest radiography(62). 
ARDS-induced respiratory failure has a high mortality 
rate (50 to 70%), with most cases caused by sepsis and 
immunosuppressive therapy(58). Pulmonary infections 
predispose to ARDS onset and, in a study conducted in 
2015, of 60 kidney transplant patients who developed 
pneumonia, 35 developed ARDS(46). 
In a retrospective multicenter study including 200 
kidney transplant patients admitted to the Intensive Care Unit 
(ICU) with ARF, 15.5% were diagnosed with ARDS. The 
events of graft rejection and immunosuppressive therapy, in 
addition to previous pulmonary infections, predispose to an 
increased risk for development of ARDS(43).  According to 
the retrospective study published in 2010, 24 of 53 patients 
with pulmonary mycosis died, mostly because of ARDS 
(17%)(10).
Length of hospital stay
No studies were found showing an average length 
of hospital stay for kidney transplant patients due to 
complications and risks that each patient might develop 
over time. Many factors may contribute to the risk 
of infections, such as the immunosuppressive profile 
adopted, postoperative care and exposure to various 
infectious diseases. In addition to these, the unfavorable 
socioeconomic profile contributes to increase the incidence 
of such complications, in developing countries(63).
Episodes of infections are usually more common in the 
first months of monitoring of the renal transplant recipient 
and are directly related to the use of immunosuppressant, 
mainly focusing the urinary tract and the surgical wound. 
Between the second and sixth months, opportunistic 
infections caused by viral or fungal agents are predominant. 
After six months, infections of community origins 
predominate(64).
Mechanical ventilation and non-invasive mechanical 
ventilation
The main pulmonary complications found in the 
postoperative period are atelectasis, tracheobronchial 
infections, pneumonia and respiratory failure(65). The 
consequences of such complications are an intrapulmonary 
arteriovenous shunt, thickening of the alveolar membrane 
and parenchymal inflammation, with resulting edema and 
fibrosis. Lungs become unable to provide the blood with 
enough oxygen, causing severe dyspnea, requiring invasive 
or non-invasive mechanical ventilation. If not reversed, 
such condition can lead to death(66).
Community-acquired pneumonia and ventilator-
associated pneumonia (VAP) were also found as reports 
of pulmonary complications in renal transplant patients 
in the late postoperative period, reporting the need for 
use of mechanical ventilation or non-invasive mechanical 
ventilation in this patient profile(40,49). Some authors report 
in their studies that patients have received treatment with 
mechanical ventilation and non-invasive mechanical 
ventilation because of respiratory failure. The ARF is a 
respiratory dysfunction caused by changes in oxygenation 
or CO² supply, which does not meet the metabolic needs 
of the body in terms of gas exchange. ARF can result 
from pulmonary or non-pulmonary conditions: ARDS, 
pneumonia, atelectasis, pulmonary edema, pulmonary 
embolism and COPD(8,13,46,52).
Some of the authors studied also mention that the 
patients included in their respective studies have required 
mechanical ventilation and non-invasive mechanical 
ventilation, without specifying the reasons for such 
procedure or addressing this issue(5,12,16,28,29,38).
Causes of death 
Of the 52 articles, 27 describe the causes related to death. 
The series of deaths shows a mortality rate ranging from 1% 
to 33%, and the main causes were pneumonia, severe sepsis 
and tuberculosis(7-10,13,14,16,20,21,23,24,28,29,33,35,36,38-41,46,48,49,51,52,56,59).
The incidence of P. jirovecii pneumonia is found at 4% 
in kidney transplant recipients, 4% in heart recipients, 11% 
in liver recipients, and 33% in heart and lung recipients(67). 
Pneumocystis jirovecii causes an intra-alveolar pneumonitis 
due to the occupation of the airspaces by a protein-rich 
exudate, which may result in pulmonary complications and 
death(66).
The high mortality from severe sepsis and septic shock 
is closely related to the approach to the infectious agent. 
The therapeutic management, including the antimicrobial 
therapy, will differ substantially according to the primary 
infection site. Inadequate initial choice of antimicrobial 
therapy can lead to a significant increase in the mortality 
rate in septic patients(68).
Despite the potential toxicity of antituberculosis 
treatment in patients admitted to the Intensive Care Unit 
(ICU), it is suggested that medications be started before 
the results of diagnostic tests, since delaying the beginning 
of treatment may result in death. In immunocompromised 
patients, the index of suspicion should be even greater. 
Patients with tuberculosis hospitalized in ICUs may 
develop other complications, such as ventilator-associated 
pneumonia, multiple organ failure, septic shock, acute 
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renal failure, disseminated intravascular coagulation, and 
gastrointestinal bleeding. Acute respiratory failure caused 
by tuberculosis and requiring MV has been associated with 
mortality rates between 17.5% and 81.0%(69).
The current study has some limitations. The studies 
included in this review do not report the reason for 
the patient’s clinical outcomes, as regards the need for 
mechanical ventilation, length of stay and percentage of 
deaths, thus rendering diffuse the knowledge of these 
aspects in this profile of patients. It is suggested that further 
studies be carried out, producing additional information 
on the use of mechanical ventilation, the length of stay in 
hospital or ICU, as well as the death incidences.
CONCLUSION
Based on the results obtained, it is concluded that 
the most common etiologic agents in kidney transplant 
patients on immunosuppressive regimen are P. jirovecii, 
A. fumigatus and M. tuberculosis. The occurrence of lung 
infections in kidney recipients is largely due to the use 
of immunosuppressive medication, need for long-term 
dialysis, history of graft dysfunction and/or rejection, and 
interhuman transmission.
The frequency of infection by these agents is high, 
particularly in immunosuppressed patients, as are the kidney 
recipients. The most common symptoms are progressive 
dyspnea and ARF, requiring invasive and non-invasive 
mechanical ventilation. The evolution of lung infections 
can lead to severe complications such as ARDS, with a high 
death rate.
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